Available IPD datapackage for study 'A Randomized, Single Blind, 3-Period, 3-Treatment, Single-dose, Crossover Study to Assess the Relative Bioavailability of BGF Propellant 1 and BGF Propellant 2 Compared With BGF MDI HFA in Healthy Subjects'

The study will evaluate bioavailability, pharmacokinetics, safety, and tolerability of
budesonide, glycopyrronium and formoterol (BGF) metered dose inhaler (MDI) formulated with 3
different propellants: Propellant 1 (Treatment A [test]), Propellant 2 (Treatment B [test])
and Hydrofluoroalkane (HFA) (Treatment C [reference]).